Conclusions:
Despite the myriad medications available, inflammation control in JIA patients is particularly difficult to achieve. The rate of medication side effects is remarkably low. It remains unclear which treatment modality is best to use for what JIA subtype. Prospective, randomized, double blind clinical trials in this regard are warranted.